Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25645505 | 1.00 | NCF1 (0.32) | NCF1SIGMAR1 | |
| SCHEMBL29340109 | 1.00 | NCF1 (0.32) | NCF1SIGMAR1 | |
| SCHEMBL22704393 | 1.00 | NCF1 (0.32) | NCF1SIGMAR1 | |
| SCHEMBL24697015 | 0.93 | NCF1 (0.33) | NCF1SIGMAR1 | |
| SCHEMBL16392548 | 0.93 | NCF1 (0.33) | NCF1SIGMAR1 | |
| SCHEMBL20031371 | 0.91 | NCF1 (0.34) | NCF1SIGMAR1 | |
| SCHEMBL20031461 | 0.91 | NCF1 (0.34) | NCF1SIGMAR1 | |
| SCHEMBL22704386 | 0.91 | NCF1 (0.34) | NCF1SIGMAR1 | |
| SCHEMBL15448046 | 0.86 | NCF1 (0.34) | NCF1SIGMAR1 | |
| SCHEMBL22704391 | 0.86 | CHRNB2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400505-A1 | PEPTIDE-UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOF | Bivision Pharmaceuticals, Inc (CN) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023083209-A1 | LIGAND COMPOUND TARGETING PSMA ANTIGEN, AND CHELATE AND USE THEREOF IN DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | 苏州瑞核医药科技有限公司 | 2023-05-19 | — | — | WO | disclosed |
| EP-3733663-A1 | QUINAZOLINE DERIVATIVE AND USE THEREOF | Medshine Discovery Inc. (CN) | 2020-11-04 | — | — | EP | disclosed |
| US-8450306-B2 | Bradykinin B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| EP-2402329-A1 | Analgetic phenylsulphonamides | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110294775-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110021488-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021488-A1 | New Compounds | ABCG2, ADORA2B, ADORA3 | NCF1 3454/4885SIGMAR1 128/4885 |
| US-20110294775-A1 | NOVEL COMPOUNDS | TRPV1, OPRL1, TRPA1 | NCF1 1142/4885SIGMAR1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.